Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Clinical Immunology · Activated PI3K-delta Syndrome Type 2

Building Your Multidisciplinary Care Team

At a Glance

APDS2 is best managed by a coordinated team led by a clinical immunologist. Patients can improve visits by gathering genetic, imaging, immune-test, biopsy, infection, and medication records and ensuring specialists share results to monitor lung, blood, and digestive complications.

Because APDS2 is a multisystem disorder, it cannot be managed by a single doctor. Effective care requires a “care neighborhood”—a group of specialists coordinated by a central “quarterback” [1][2]. This central role is almost always held by a Clinical Immunologist who specializes in inborn errors of immunity [3].

Your Core Specialty Team

Each specialist on your team manages a specific “domain” of the disease to prevent long-term complications. Referrals should be based on your individual manifestations, rather than expecting everyone to need the full list below.

  • Clinical Immunologist: This is your primary specialist. They manage immunoglobulin replacement therapy (IRT), oversee targeted medications like leniolisib or sirolimus, and monitor your overall immune “census” (lymphocyte subsets) [4][3].
  • Primary Care Clinician: Essential for general health maintenance and coordinating local care.
  • Pulmonologist (Lung Specialist): Since respiratory issues are common in APDS2, a pulmonologist is essential to monitor for bronchiectasis (permanent airway damage) and provide airway clearance support [5][6].
  • Hematologist/Oncologist: This specialist is consulted if you develop cytopenias (low blood counts) or require monitoring for lymphoma [7][8]. They are also the experts if a stem cell transplant (HSCT) is evaluated.
  • Gastroenterologist (GI Specialist): Roughly 24% of patients experience chronic diarrhea or inflammatory bowel issues [9]. A GI specialist can perform endoscopies to distinguish between infection and immune-driven inflammation [8].
  • Clinical Geneticist / Genetic Counselor: They help interpret the specific PIK3R1 variant and provide guidance for family members who may want to be screened [4][7]. A pharmacist and psychosocial support services can also be highly beneficial additions.

The First Major Specialist Visit

When you see an APDS2 specialist for the first time, you are establishing a baseline—a “snapshot” of your health that all future tests will be compared against [10]. To make this visit productive, ensure the specialist has access to the following artifacts. (Note: You do not always need to carry these physically; your doctor’s office can often request the files directly.)

  1. Genetic Test Reports: Not just the summary, but the full lab report showing the specific variant [11].
  2. Imaging Disks: Bring the actual digital files (DICOM files on a CD or USB) for any chest CT scans or PET scans. Specialists often need to view the images themselves, not just read the radiologist’s report [6][12].
  3. Flow Cytometry Results: These are the specialized “immune census” reports that show your counts for naive, transitional, and senescent cells [9][11].
  4. Pathology Reports/Slides: If you have ever had a lymph node biopsy or a colonoscopy biopsy, having the actual pathology slides available for a second review by an expert hematopathologist can be critical [13][8].
  5. Infection History: A list or log of every hospitalization, course of antibiotics, and chronic infection (like sinus or ear infections) you have experienced, alongside a medication list [10].

Organizing for Success

Fragmented care—where one doctor doesn’t know what the other is doing—is one of the biggest challenges for rare disease families [2]. Research indicates that patients who receive care at a centralized Primary Immunodeficiency (PI) referral center often have better-coordinated monitoring [1][3]. If you are not at a referral center, ensure your immunologist is willing to communicate directly with your pulmonologist and hematologist to review your status regularly [10].

Common questions in this guide

What type of doctor should lead my APDS2 care?
A clinical immunologist who specializes in inborn errors of immunity is usually the central coordinator, or “quarterback,” for APDS2 care. This doctor can track immune testing and treatment while communicating with primary care and specialists for the lungs, blood, digestive system, and genetics.
Which records should I bring to my first APDS2 specialist visit?
Bring or ask your medical offices to send the full genetic report, chest CT or PET image files, immune-cell count reports, biopsy pathology reports or slides, infection history, and current medication list. Having these records together gives the team a baseline for future monitoring.
Why is lung monitoring important in APDS2?
Respiratory problems are common in APDS2, and a pulmonologist can check for bronchiectasis, which is permanent airway damage, and recommend airway-clearance support. Monitoring may be useful even when breathing symptoms are not obvious.
Which specialists may be part of an APDS2 care team?
The team may include primary care, clinical immunology, pulmonology, hematology or oncology, gastroenterology, clinical genetics, genetic counseling, and pathology experts. The exact team depends on each person’s problems, such as lung disease, low blood counts, digestive inflammation, or a need to evaluate lymphoma.
How can I keep my APDS2 doctors from working separately?
Care at a primary immunodeficiency referral center may make monitoring more coordinated. If care is spread across different practices, ask your immunologist to communicate directly with your pulmonologist and hematologist or oncologist and review results on a regular schedule.
What treatments might an APDS2 immunologist monitor?
A clinical immunologist may manage immunoglobulin replacement therapy and oversee targeted medicines such as leniolisib or sirolimus. Hematology or oncology may become involved if cytopenias or lymphoma occur or if hematopoietic stem cell transplantation is being considered.

Get notified when new evidence is published on immunodeficiency 132b.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.

    Barzaghi F, Moratti M, Panza G, et al.

    Journal of clinical immunology 2024; (45(1)):58.

    PMID: 39714594
  2. 2

    Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

    Wolf HM, Candotti F, Spelsberg R, et al.

    Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.

    PMID: 41859081
  3. 3

    Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).

    Neth O, Alsina L, Rivière JG, et al.

    Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.

    PMID: 40028901
  4. 4

    Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.

    Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.

    Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.

    PMID: 35789397
  5. 5

    Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.

    Condliffe AM, Chandra A

    Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.

    PMID: 29556229
  6. 6

    Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

    Coulter TI, Chandra A, Bacon CM, et al.

    The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.

    PMID: 27555459
  7. 7

    Case Report: Early-onset or recalcitrant cytopenias as presenting manifestations of activated PI3Kδ syndrome.

    Remiker AS, Lopes JPM, Jesudas R, et al.

    Frontiers in pediatrics 2024; (12()):1494945 doi:10.3389/fped.2024.1494945.

    PMID: 39664282
  8. 8

    Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.

    Rivalta B, Amodio D, Milito C, et al.

    Frontiers in pediatrics 2021; (9()):703853 doi:10.3389/fped.2021.703853.

    PMID: 34540765
  9. 9

    Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.

    Elkaim E, Neven B, Bruneau J, et al.

    The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.

    PMID: 27221134
  10. 10

    Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application.

    Upton JEM, Williams KW, Cant A, et al.

    PloS one 2025; (20(10)):e0333341 doi:10.1371/journal.pone.0333341.

    PMID: 41091701
  11. 11

    Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study.

    Del Pino Molina L, Reche Yebra K, Soto Serrano Y, et al.

    Frontiers in immunology 2024; (15()):1476218 doi:10.3389/fimmu.2024.1476218.

    PMID: 39620215
  12. 12

    The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.

    Catelli A, Nanni C, Mulè R, et al.

    Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082203.

    PMID: 38673479
  13. 13

    Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.

    Zhao X, Ming X, Shang Z, et al.

    Case reports in hematology 2026; (2026()):3644513 doi:10.1155/crh/3644513.

    PMID: 42591980

This page is for informational purposes only and does not constitute medical advice about APDS2 care. Your clinical immunologist and other specialists should tailor monitoring, referrals, and treatment to your needs.